Abstract
Human epidermal growth factor receptor 2 (HER2) is over-expressed in 15% – 30% of breast cancers. Women with HER2-positive breast cancer tend to have more aggressive cancer, increased risk of recurrence, and less favorable survival outcomes than women with HER2-negative breast cancer. This review focuses on HER2 and its role in breast cancer pathogenesis. We begin by providing background information on the biological function of HER2 and how this gene contributes to breast cancer development and progression. Next, we review the ongoing debate surrounding the accuracy of available modalities for detecting HER2, namely fluorescence in-situ hybridization (FISH) versus immunohistochemistry (IHC). We include current data examining the relationship between HER2 and possible genetic modifiers, such as topoisomerase IIα, BRCA1, and genomic instability in breast cancer subjects, and how these relationships may influence response to current therapies directed against HER2. We then discuss trastuzumab, a monoclonal antibody used to treat HER2+ breast cancers, and, after providing an overview of the molecular processes involved in targeted therapy, we summarize the current literature regarding outcomes, as well as the potential impact on the overall health of patients, with special attention to cardiac risk involved with such therapy. Finally, we touch on future directions in this field, including newer targeted therapies in development.
Keywords: HER2, breast cancer, human epidermal growth factor receptor
Current Cancer Therapy Reviews
Title: HER2 in the Era of Molecular Medicine: A Review
Volume: 4 Issue: 1
Author(s): Karen A. Callaghan, Rachel E. Ellsworth, Darrell L. Ellsworth and Craig D. Shriver
Affiliation:
Keywords: HER2, breast cancer, human epidermal growth factor receptor
Abstract: Human epidermal growth factor receptor 2 (HER2) is over-expressed in 15% – 30% of breast cancers. Women with HER2-positive breast cancer tend to have more aggressive cancer, increased risk of recurrence, and less favorable survival outcomes than women with HER2-negative breast cancer. This review focuses on HER2 and its role in breast cancer pathogenesis. We begin by providing background information on the biological function of HER2 and how this gene contributes to breast cancer development and progression. Next, we review the ongoing debate surrounding the accuracy of available modalities for detecting HER2, namely fluorescence in-situ hybridization (FISH) versus immunohistochemistry (IHC). We include current data examining the relationship between HER2 and possible genetic modifiers, such as topoisomerase IIα, BRCA1, and genomic instability in breast cancer subjects, and how these relationships may influence response to current therapies directed against HER2. We then discuss trastuzumab, a monoclonal antibody used to treat HER2+ breast cancers, and, after providing an overview of the molecular processes involved in targeted therapy, we summarize the current literature regarding outcomes, as well as the potential impact on the overall health of patients, with special attention to cardiac risk involved with such therapy. Finally, we touch on future directions in this field, including newer targeted therapies in development.
Export Options
About this article
Cite this article as:
Callaghan A. Karen, Ellsworth E. Rachel, Ellsworth L. Darrell and Shriver D. Craig, HER2 in the Era of Molecular Medicine: A Review, Current Cancer Therapy Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339408783565529
DOI https://dx.doi.org/10.2174/157339408783565529 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Electroconvulsive Therapy in Child and Adolescent Psychiatry
Current Psychiatry Reviews The Role of local Insulin-like Growth Factor-1 Isoforms in the Pathophysiology of Skeletal Muscle
Current Genomics Cardiovascular Risk Factors, Metabolic Complications, & the Natural Course of CKD in Children
Current Hypertension Reviews Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Stem Cell Research & Therapy Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Genes Involved in Hereditary Hearing Impairment
Current Genomics Morphological and Molecular Changes of the Myocardium After Left Ventricular Mechanical Support
Current Cardiology Reviews Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Myocardial Infarction with Non Obstructive Coronary Atherosclerosis: A Case Report
New Emirates Medical Journal MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) A Narrative Review of Recent Studies on the Role of Vitamin D in the Prevention of Cardiac and Renal Risk and Additional Considerations for COVID-19 Vulnerability
Current Vascular Pharmacology The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued)